Fianlimab (REGN3767) is a monoclonal antibody that targets human lymphocyte activation gene 3 (LAG-3) and exhibits antitumor activity. By blocking the immune checkpoint receptor LAG-3, fianlimab reverses T-cell exhaustion, thereby enhancing the antitumor immune response. Fianlimab is being investigated for use in the treatment of solid tumors such as melanoma.

Methods: Human primary CD8⁺/CD4⁺ T cells were treated with Fianlimab (1–10 μg/mL) and cultured for 48–72 hours. Cell proliferation was assessed by flow cytometry, and cytokine secretion was measured by ELISA.
Results: Fianlimab effectively reversed T-cell exhaustion, promoted IFN-γ secretion, and restored T-cell cytotoxic function. [1]

Methods: A MC38.Ova colon cancer xenograft model was established in mice. Fianlimab (5–25 mg/kg) was administered intraperitoneally twice weekly for 2 weeks, and tumor growth and changes in the immune microenvironment were monitored.
Results: Fianlimab inhibited tumor growth and significantly increased the infiltration and activation of effector CD8⁺ T cells within the tumor, thereby improving the immunosuppressive microenvironment. [1]

Human

Immobilized Human LAG-3 Protein (His) at 2 μg/mL (30 μL/well) can bind Fianlimab. The EC50 is 0.03073 μg/mL.

Monoclonal

Unconjugated